Strategies and challenges for the next generation of therapeutic antibodies

被引：642

作者：

Beck, Alain ^{[1
]}

Wurch, Thierry ^{[1
]}

Bailly, Christian ^{[1
]}

Corvaia, Nathalie ^{[1
]}

机构：

[1] CIPF, F-74160 St Julien En Genevois, France

来源：

NATURE REVIEWS IMMUNOLOGY | 2010年 / 10卷 / 05期

关键词：

MONOCLONAL-ANTIBODIES; CANCER-THERAPY; COLORECTAL-CANCER; DRUG; GLYCOSYLATION; BINDING; MOUSE; IDENTIFICATION; OPTIMIZATION; SPECIFICITY;

D O I：

10.1038/nri2747

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful strategies used by pharmaceutical companies so far to bring innovative drugs to the market. Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best therapeutic antigen targets, to optimize the structure of IgG antibodies and to design related or new structures with additional functions.

引用

收藏

页码：345 / 352

页数：8

相关论文

共 71 条

[1] What's fueling the biotech engine-2008 [J].

Aggarwal, Saurabh .

NATURE BIOTECHNOLOGY, 2009, 27 (11) :987-993

[2]

[Anonymous], 1997, BIOCH BIOPHYSICA ACT

[3] Extending Mass Spectrometry Contribution to Therapeutic Monoclonal Antibody Lead Optimization: Characterization of Immune Complexes Using Noncovalent ESI-MS [J].

Atmanene, Cedric ;

Wagner-Rousset, Elsa ;

Malissard, Martine ;

Chol, Bertrand ;

Robert, Alain ;

Corvaia, Nathalie ;

Van Dorsselaer, Alain ;

Beck, Alain ;

Sanglier-Cianferani, Sarah .

ANALYTICAL CHEMISTRY, 2009, 81 (15) :6364-6373

[4] Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 [J].

Baselga, Jose ;

Swain, Sandra M. .

NATURE REVIEWS CANCER, 2009, 9 (07) :463-475

[5] Editorial: Therapeutic Antibodies and Derivatives: From the Bench to the Clinic [J].

Beck, A. ;

Wurch, T. ;

Corvaia, N. .

CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2008, 9 (06) :421-422

[6]

BECK A, 2009, MABS, V1, P394

[7]

BECK A, 2009, MABS, V2, P108

[8] GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins [J].

Beck, Alain ;

Cochet, Olivier ;

Wurch, Thierry .

EXPERT OPINION ON DRUG DISCOVERY, 2010, 5 (01) :95-111

[9] Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins [J].

Beck, Alain ;

Wagner-Rousset, Elsa ;

Bussat, Marie-Claire ;

Lokteff, Maryline ;

Klinguer-Hamour, Christine ;

Haeuw, Jean-Francois ;

Goetsch, Liliane ;

Wurch, Thierry ;

Van Dorsselaer, Alain ;

Corvaia, Nathalie .

CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2008, 9 (06) :482-501

[10] Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site [J].

Bostrom, Jenny ;

Yu, Shang-Fan ;

Kan, David ;

Appleton, Brent A. ;

Lee, Chingwei V. ;

Billeci, Karen ;

Man, Wenyan ;

Peale, Franklin ;

Ross, Sarajane ;

Wiesmann, Christian ;

Fuh, Germaine .

SCIENCE, 2009, 323 (5921) :1610-1614

← 1 2 3 4 5 6 7 8 →